HIK Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£19.37 |
| 52 Week High | UK£23.60 |
| 52 Week Low | UK£17.50 |
| Beta | 0.45 |
| 1 Month Change | -10.98% |
| 3 Month Change | -3.82% |
| 1 Year Change | 3.64% |
| 3 Year Change | -4.63% |
| 5 Year Change | -11.15% |
| Change since IPO | 586.88% |
Recent News & Updates
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Mar 17
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Mar 10 Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Recent updates
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Mar 17R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Mar 10 Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Shareholder Returns
| HIK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -3.6% | -0.4% | -1.0% |
| 1Y | 3.6% | 2.7% | 5.4% |
Return vs Industry: HIK matched the UK Pharmaceuticals industry which returned 3.8% over the past year.
Return vs Market: HIK underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 9.9% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: HIK has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HIK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,500 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| HIK fundamental statistics | |
|---|---|
| Market cap | UK£4.27b |
| Earnings (TTM) | UK£276.56m |
| Revenue (TTM) | UK£2.41b |
15.4x
P/E Ratio1.8x
P/S RatioIs HIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIK income statement (TTM) | |
|---|---|
| Revenue | US$3.13b |
| Cost of Revenue | US$1.71b |
| Gross Profit | US$1.42b |
| Other Expenses | US$1.06b |
| Earnings | US$359.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 07, 2025
| Earnings per share (EPS) | 1.63 |
| Gross Margin | 45.25% |
| Net Profit Margin | 11.48% |
| Debt/Equity Ratio | 53.8% |
How did HIK perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield49%
Payout RatioDoes HIK pay a reliable dividends?
See HIK dividend history and benchmarks| Hikma Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Mar 20 2025 |
| Dividend Pay Date | May 01 2025 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 28 days |
Does HIK pay a reliable dividends?
See HIK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/02 06:26 |
| End of Day Share Price | 2025/04/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 37 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| Emily Field | Barclays |
| Simon Mather | Barclays |